Latest ADCT news

These beaten-down stocks could bounce back in January, if history is any guide

Market Watch · Mon, 21 Sep 2026 17:06:00 -0400

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

PRNewsWire · Thu, 03 Sep 2026 07:15:00 -0400

LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m.

ADC Therapeutics Q2 Earnings Call Highlights

MarketBeat · Thu, 13 Aug 2026 16:05:39 -0400

ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's commercial performance remained broadly consistent with recent quarters.

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · Thu, 13 Aug 2026 14:47:18 -0400

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · Thu, 13 Aug 2026 09:51:05 -0400

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

PRNewsWire · Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

PRNewsWire · Thu, 06 Aug 2026 07:30:00 -0400

LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates.

Market information is provided for research and visualization and is not investment advice.